Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives Consensus Rating of “Reduce” from Analysts

Seres Therapeutics, Inc. (NASDAQ:MCRB) has been given an average recommendation of “Reduce” by the five ratings firms that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $73.67.

MCRB has been the subject of a number of research reports. The Goldman Sachs Group dropped their price objective on Seres Therapeutics from $20.00 to $15.00 and set a “sell” rating for the company in a research note on Friday, March 14th. Chardan Capital reiterated a “neutral” rating and set a $6.00 price target (up from $1.25) on shares of Seres Therapeutics in a research note on Thursday. Finally, StockNews.com raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday.

Seres Therapeutics Price Performance

NASDAQ MCRB opened at $7.05 on Friday. The stock has a market capitalization of $61.46 million, a P/E ratio of -30.65 and a beta of 2.89. The firm’s 50-day moving average is $11.67 and its two-hundred day moving average is $14.66. Seres Therapeutics has a 12 month low of $6.64 and a 12 month high of $30.60.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported ($2.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($1.57). As a group, analysts anticipate that Seres Therapeutics will post -0.38 EPS for the current year.

Institutional Trading of Seres Therapeutics

A number of large investors have recently made changes to their positions in the company. Avantax Advisory Services Inc. grew its holdings in Seres Therapeutics by 170.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 28,500 shares in the last quarter. SBI Securities Co. Ltd. grew its stake in shares of Seres Therapeutics by 221.8% during the first quarter. SBI Securities Co. Ltd. now owns 69,664 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 48,013 shares in the last quarter. Jane Street Group LLC increased its holdings in Seres Therapeutics by 181.4% in the fourth quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 37,866 shares during the last quarter. Virtu Financial LLC raised its stake in Seres Therapeutics by 44.8% in the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 18,191 shares in the last quarter. Finally, Northern Trust Corp raised its stake in Seres Therapeutics by 20.4% in the fourth quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company’s stock valued at $218,000 after buying an additional 44,461 shares in the last quarter. 59.34% of the stock is currently owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.